News Alkermes closing in on Biogen with MS rival ALKS 8700 may have fewer side effects than Tecfidera.
News Biogen takes on Tecfidera adherence issues Company hopes to coach patients with stomach side-effects.
News Biogen drug shows potential in Alzheimer's Phase 1b trial shows aducanumab clears brain plaques.
News Biogen’s haemophilia spin-out Bioverativ to launch early 201... Coming antibody drugs and gene therapy could transform treatment
News Dexcom is first to join FDA/CMS health tech pilot The FDA has named Dexcom as the first company to take part in its TEMPO pilot, which aims to bring digital health tech to patients more quickly.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
